$AORT

Berry Lance A sold $20K of AORT

Berry Lance A (EVP, COO, CFO & Treasurer) sold 715 shares of ARTIVION, INC. (AORT) at $28.55 on 2026-08-14.

Original reporting
SEC EDGAR · Berry Lance A
Published Aug 17, 2026, 7:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
medium confidence
Mentioned
$AORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) by an officer; it provides sentiment context but no operational or financial guidance change.

02

Market read

Traders may note insider selling, but the disclosed dollar value is small and lacks a fundamental catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings (210,112 shares) suggest the insider remains materially invested.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-17, covering a sale dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralMedium confidence
Context

Artivion Form 4 shows EVP Berry Lance A sold 715 shares at $28.5490 on 2026-08-14, totaling $20,412.54.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction size ($20.4k) is small relative to typical market impact, and there is no accompanying corporate event or guidance change.

Market effects

No clear sector read-through from a small insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • Artivion, Inc.

    Company whose insider transaction is disclosed via Form 4.

  • Berry Lance A

    EVP, COO, CFO & Treasurer who sold 715 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMed

Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

$AORTMed

Why Artivion (AORT) Stock Is Trading Up Today

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

$AORTMedAI 8/10

Artivion (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

$AORTMed

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.